In today’s session GW Pharmaceuticals PLC- ADR (GWPH) registered an unusually high (600) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious GWPH increase. With 600 contracts traded and 2324 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: GWPH161118C00115000 closed last at: $14.7 or 53.1% up. About 50,722 shares traded hands. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has risen 62.87% since April 11, 2016 and is uptrending. It has outperformed by 56.72% the S&P500.
Analysts await GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to report earnings on December, 5. They expect $-1.59 earnings per share, down 87.06% or $0.74 from last year’s $-0.85 per share. After $-0.73 actual earnings per share reported by GW Pharmaceuticals PLC- ADR for the previous quarter, Wall Street now forecasts 117.81% negative EPS growth.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Ratings Coverage
Out of 8 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. $182 is the highest target while $129 is the lowest. The $150.20 average target is 17.03% above today’s ($128.34) stock price. GW Pharmaceuticals has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Morgan Stanley initiated GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) rating on Thursday, August 13. Morgan Stanley has “Overweight” rating and $150 price target. Cantor Fitzgerald maintained it with “Buy” rating and $182 target price in Monday, September 26 report. The firm earned “Buy” rating on Friday, June 3 by Cantor Fitzgerald. The firm has “Sell” rating given on Monday, June 27 by Janney Capital. The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has “Buy” rating given on Friday, October 7 by Goldman Sachs. On Monday, November 30 the stock rating was initiated by TH Capital with “Buy”. The firm has “Buy” rating by Roth Capital given on Monday, March 14. The firm has “Hold” rating given on Friday, August 26 by Numis Securities. Roth Capital initiated GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) rating on Monday, November 30. Roth Capital has “Buy” rating and $130 price target.
According to Zacks Investment Research, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.”
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The company has a market cap of $3.21 billion. The Firm develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. It currently has negative earnings. The Firm operates through three divisions: Commercial, Sativex Research and Development , and Pipeline Research and Development.
More notable recent GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) news were published by: Investorplace.com which released: “GW Pharmaceuticals (GWPH) Stock Landed a 1-2 Ballot Punch” on November 11, 2016, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on April 27, 2013, Marketwatch.com published: “GW Pharmaceuticals PLC ADR” on May 08, 2013. More interesting news about GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) were released by: Investorplace.com and their article: “GW Pharmaceuticals PLC- ADR Is a First-Rate Marijuana Stock (GWPH)” published on September 26, 2016 as well as Investorplace.com‘s news article titled: “GW Pharmaceuticals PLC- ADR (GWPH) Boards the Buyout Rumor Mill” with publication date: September 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.